Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Xinlay Not Ready For Approval Or Abandonment, Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Oncologic Drugs Advisory Committee unanimously recommends against approval of Abbott's prostate cancer therapy atrasentan.
Advertisement

Related Content

Xinlay Phase III Back-Up Trial Winding Down
Xinlay Phase III Back-Up Trial Winding Down
Abbott Receives Xinlay “Not Approvable” Letter
Abbott Receives Xinlay “Not Approvable” Letter
Dendreon Provenge Plant Completion Is Last Hurdle Before BLA Filing
Dendreon Provenge Plant Completion Is Last Hurdle Before BLA Filing
Abbott Xinlay Lack Of Efficacy, CV Safety Will Be Likely Focus Of Advisory Cmte. Review
Abbott Xinlay Lack Of Efficacy, CV Safety Will Be Likely Focus Of Advisory Cmte. Review
Ongoing Phase III Study Could Provide Xinlay Back-Up Option, Abbott Says
Abbott Atrasentan Meta-Analysis Of Failed Trials Is "Centerpiece" Of NDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS062869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel